Daniel J Antoine1, Rosalind E Jenkins2, James W Dear3, Dominic P Williams2, Mitchell R McGill4, Matthew R Sharpe5, Darren G Craig6, Kenneth J Simpson6, Hartmut Jaeschke4, B Kevin Park2. 1. MRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK. Electronic address: d.antoine@liv.ac.uk. 2. MRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK. 3. University/BHF Centre for Cardiovascular Science, Edinburgh University & NPIS Edinburgh, Scottish Poisons Information Bureau, Edinburgh, UK. 4. Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA. 5. Department of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA. 6. Scottish Liver Transplantation Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
Abstract
BACKGROUND & AIMS: Full length keratin-18 (FL-K18) and High Mobility Group Box-1 (HMGB1) represent circulating indicators of necrosis during acetaminophen (APAP) hepatotoxicity in vivo. In addition, the caspase-cleaved fragment of K18 (cK18) and hyper-acetylated HMGB1 represent serum indicators of apoptosis and immune cell activation, respectively. The study aim was to assess their mechanistic utility to establish the balance between apoptosis, necrosis, and immune cell activation throughout the time course of clinical APAP hepatotoxicity. METHODS: HMGB1 (total, acetylated) and K18 (apoptotic, necrotic) were identified and quantified by novel LC-MS/MS assays in APAP overdose patients (n=78). RESULTS: HMGB1 (total; 15.4±1.9ng/ml, p<0.01, acetylated; 5.4±2.6ng/ml, p<0.001), cK18 (5649.8±721.0U/L, p<0.01), and FL-K18 (54770.2±6717.0U/L, p<0.005) were elevated in the sera of APAP overdose patients with liver injury compared to overdose patients without liver injury and healthy volunteers. HMGB1 and FL-K18 correlated with alanine aminotransferase (ALT) activity (R(2)=0.60 and 0.58, respectively, p<0.0001) and prothrombin time (R(2)=0.62 and 0.71, respectively, p<0.0001). Increased total and acetylated HMGB1 and FL-K18 were associated with worse prognosis (King's College Criteria) or patients that died/required liver transplant compared to spontaneous survivors (all p<0.05-0.001), a finding not reflected by ALT and supported by ROC analysis. Acetylated HMGB1 was a better predictor of outcome than the other markers of cell death. CONCLUSIONS: K18 and HMGB1 represent blood-based tools to investigate the cell death balance clinical APAP hepatotoxicity. Activation of the immune response was seen later in the time course as shown by the distinct profile of acetylated HMGB1 and was associated with worse outcome. Copyright Â
BACKGROUND & AIMS: Full length keratin-18 (FL-K18) and High Mobility Group Box-1 (HMGB1) represent circulating indicators of necrosis during acetaminophen (APAP) hepatotoxicity in vivo. In addition, the caspase-cleaved fragment of K18 (cK18) and hyper-acetylated HMGB1 represent serum indicators of apoptosis and immune cell activation, respectively. The study aim was to assess their mechanistic utility to establish the balance between apoptosis, necrosis, and immune cell activation throughout the time course of clinical APAPhepatotoxicity. METHODS:HMGB1 (total, acetylated) and K18 (apoptotic, necrotic) were identified and quantified by novel LC-MS/MS assays in APAP overdosepatients (n=78). RESULTS:HMGB1 (total; 15.4±1.9ng/ml, p<0.01, acetylated; 5.4±2.6ng/ml, p<0.001), cK18 (5649.8±721.0U/L, p<0.01), and FL-K18 (54770.2±6717.0U/L, p<0.005) were elevated in the sera of APAP overdosepatients with liver injury compared to overdosepatients without liver injury and healthy volunteers. HMGB1 and FL-K18 correlated with alanine aminotransferase (ALT) activity (R(2)=0.60 and 0.58, respectively, p<0.0001) and prothrombin time (R(2)=0.62 and 0.71, respectively, p<0.0001). Increased total and acetylated HMGB1 and FL-K18 were associated with worse prognosis (King's College Criteria) or patients that died/required liver transplant compared to spontaneous survivors (all p<0.05-0.001), a finding not reflected by ALT and supported by ROC analysis. Acetylated HMGB1 was a better predictor of outcome than the other markers of cell death. CONCLUSIONS:K18 and HMGB1 represent blood-based tools to investigate the cell death balance clinical APAPhepatotoxicity. Activation of the immune response was seen later in the time course as shown by the distinct profile of acetylated HMGB1 and was associated with worse outcome. Copyright Â
Authors: Pavel Strnad; Qin Zhou; Shinichiro Hanada; Laura C Lazzeroni; Bi Hui Zhong; Phillip So; Timothy J Davern; William M Lee; M Bishr Omary Journal: Gastroenterology Date: 2010-06-09 Impact factor: 22.682
Authors: C David Williams; Daniel J Antoine; Patrick J Shaw; Craig Benson; Anwar Farhood; Dominic P Williams; Thirumala-Devi Kanneganti; B Kevin Park; Hartmut Jaeschke Journal: Toxicol Appl Pharmacol Date: 2011-03-21 Impact factor: 4.219
Authors: Anna E Rutherford; Linda S Hynan; Carolina B S Borges; David G Forcione; Jason T Blackard; Wenyu Lin; April R Gorman; Obaid Shakil Shaikh; Adrian Reuben; Edwyn Harrison; K Rajender Reddy; William M Le; Raymond T Chung Journal: Clin Gastroenterol Hepatol Date: 2007-10-29 Impact factor: 11.382
Authors: Lars P Bechmann; Guido Marquitan; Christoph Jochum; Fuat Saner; Guido Gerken; Ali Canbay Journal: Liver Int Date: 2008-05 Impact factor: 5.828
Authors: Stefan Hofer; Thorsten Brenner; Christian Bopp; Jochen Steppan; Christoph Lichtenstern; Jürgen Weitz; Thomas Bruckner; Eike Martin; Ursula Hoffmann; Markus A Weigand Journal: Crit Care Date: 2009-06-18 Impact factor: 9.097
Authors: C Dive; R A Smith; E Garner; T Ward; S St George-Smith; F Campbell; W Greenhalf; P Ghaneh; J P Neoptolemos Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640
Authors: Yiting Tang; Xin Zhao; Daniel Antoine; Xianzhong Xiao; Haichao Wang; Ulf Andersson; Timothy R Billiar; Kevin J Tracey; Ben Lu Journal: Antioxid Redox Signal Date: 2016-02-05 Impact factor: 8.401
Authors: James W Dear; Daniel J Antoine; Philip Starkey-Lewis; Christopher E Goldring; B Kevin Park Journal: Br J Clin Pharmacol Date: 2014-05 Impact factor: 4.335
Authors: Celine Hernandez; Peter Huebener; Jean-Philippe Pradere; Daniel J Antoine; Richard A Friedman; Robert F Schwabe Journal: J Clin Invest Date: 2018-05-07 Impact factor: 14.808
Authors: Benjamin L Woolbright; Daniel J Antoine; Rosalind E Jenkins; Mary Lynn Bajt; B Kevin Park; Hartmut Jaeschke Journal: Toxicol Appl Pharmacol Date: 2013-10-03 Impact factor: 4.219
Authors: Konstantin Stark; Vanessa Philippi; Sven Stockhausen; Johanna Busse; Antonella Antonelli; Meike Miller; Irene Schubert; Parandis Hoseinpour; Sue Chandraratne; Marie-Luise von Brühl; Florian Gaertner; Michael Lorenz; Alessandra Agresti; Raffaele Coletti; Daniel J Antoine; Ralf Heermann; Kirsten Jung; Sven Reese; Iina Laitinen; Markus Schwaiger; Axel Walch; Markus Sperandio; Peter P Nawroth; Christoph Reinhardt; Sven Jäckel; Marco E Bianchi; Steffen Massberg Journal: Blood Date: 2016-08-29 Impact factor: 22.113
Authors: Sanna Nyström; Daniel J Antoine; Peter Lundbäck; John G Lock; Andreia F Nita; Kari Högstrand; Alf Grandien; Helena Erlandsson-Harris; Ulf Andersson; Steven E Applequist Journal: EMBO J Date: 2012-12-07 Impact factor: 11.598
Authors: Ben Lu; Daniel J Antoine; Kevin Kwan; Peter Lundbäck; Heidi Wähämaa; Hanna Schierbeck; Melissa Robinson; Marieke A D Van Zoelen; Huan Yang; Jianhua Li; Helena Erlandsson-Harris; Sangeeta S Chavan; Haichao Wang; Ulf Andersson; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2014-01-27 Impact factor: 11.205